An update on the safety of current therapies for Alzheimer's disease: focus on rivastigmine

Therapeutic Advances in Drug Safety
Rita KhouryGeorge T Grossberg

Abstract

Alzheimer's disease (AD) is the most common cause of major neurocognitive disorders worldwide. Despite all research efforts, therapeutic options for AD are still limited to two drug classes: cholinesterase inhibitors (ChEIs) and the NMDA-receptor antagonist memantine. Donepezil, rivastigmine and galantamine are the three ChEIs FDA-approved as first-line treatment for AD. Although they share the same mode of action, they differ in terms of their pharmacologic characteristics and route of administration, which can impact their safety and tolerability profile. Rivastigmine, available in both oral and transdermal patch formulations, is a slowly reversible dual inhibitor of acetyl and butyryl cholinesterase, selective for the G1 isoform of acetylcholinesterase, without hepatic metabolism by the CYP-450 system. Despite its unique features, it has been associated with a higher incidence of adverse events in comparison to other ChEIs. The oral form, approved for the treatment of mild to moderate AD, is associated with a higher incidence of gastrointestinal side effects. The transdermal patch formulation approved for use across all stages of AD has been shown to have a better tolerability profile in comparison to both the oral form and ...Continue Reading

References

May 23, 2002·Journal of Clinical Pharmacology·Joel MorganrothRavi Anand
Aug 7, 2002·Clinical Pharmacokinetics·Michael W JannGary W Small
Jun 5, 2003·Clinical Neuropharmacology·Alberto VillarejoJuan Ruiz
Sep 16, 2005·Expert Review of Neurotherapeutics·Abhilash K Desai, George T Grossberg
Mar 14, 2007·Journal of Neurology, Neurosurgery, and Psychiatry·Howard H FeldmanUNKNOWN Study 304 Group
Jul 31, 2007·Neurology·Jeffrey CummingsSilke Appel-Dingemanse
Nov 16, 2007·Current Medical Research and Opinion·François MercierSilke Appel-Dingemanse
Dec 2, 2008·Expert Opinion on Drug Delivery·Bengt Winblad, João Carlos Machado
Dec 8, 2009·Advances in Therapy·Iris AleHoward I Maibach
Aug 17, 2010·The American Journal of Emergency Medicine·Duk Hee LeeHyung Min Lee
Apr 22, 2011·Expert Opinion on Drug Delivery·Johannes WohlrabB Tamke
Jul 5, 2011·Drugs & Aging·Laxeshkumar Patel, George T Grossberg
May 11, 2012·American Journal of Alzheimer's Disease and Other Dementias·Ahmet Turan IsikUmit Ateskan
Jun 6, 2012·Current Drug Safety·Henrik LövborgStaffan Hägg
Sep 22, 2012·Psychogeriatrics : the Official Journal of the Japanese Psychogeriatric Society·Peter Pregelj
Oct 16, 2013·Pharmacotherapy·Anthony S ZannasP Murali Doraiswamy
May 29, 2014·American Journal of Alzheimer's Disease and Other Dementias·Ahmet Turan IsikAdnan Yay
Apr 1, 2003·Current Therapeutic Research, Clinical and Experimental·George T Grossberg
Dec 18, 2014·Journal of the American Geriatrics Society·Dominique Huvent-GrelleFrançois Puisieux
Jun 3, 2015·Drugs & Aging·William James DeardorffGeorge T Grossberg
Jan 26, 2016·Expert Opinion on Drug Delivery·Jinsong HaoSam G Raney
Apr 30, 2017·Clinical Neuropharmacology·Chih-Wei HsuPao-Yen Lin
Jun 9, 2017·Clinical Toxicology : the Official Journal of the American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists·Yoshiki SuzukiTohru Kishino

❮ Previous
Next ❯

Citations

Jun 16, 2019·Drugs & Aging·Paul NoufiGeorge T Grossberg
Jan 25, 2020·Expert Opinion on Drug Safety·Andrea HaakeGeorge T Grossberg
Apr 9, 2020·Alzheimer's Research & Therapy·Carmen Hierro-BujalanceMonica Garcia-Alloza
Sep 3, 2020·Therapeutic Advances in Drug Safety·Katie Malone, Jules C Hancox
Mar 12, 2020·Biomolecules·Samir F de A CavalcanteTanos C C França
Nov 18, 2020·Neurodegenerative Disease Management·Kevin NguyenGeorge T Grossberg
Dec 12, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Zeinab Breijyeh, Rafik Karaman
Feb 12, 2021·Bioorganic Chemistry·Pritam ThapaMukut Sharma
Jun 1, 2021·ACS Central Science·Benjamin G Reed-BerendtLouis C Morrill
Jul 1, 2021·Alzheimer's & Dementia : Translational Research & Clinical Interventions·Frederick M LangMarwan Noel Sabbagh
Dec 3, 2021·Journal of the American Geriatrics Society·Prajakta P MasurkarRajender R Aparasu

❮ Previous
Next ❯

Software Mentioned

OPTIMA

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.